Brought to you by 
Chromos acquires Targeted Molecules Corp.
07 Mar 2006
Executive Summary
Cellular engineering company Chromos has acquired privately held Targeted Molecules Corp. (therapeutic antibodies R&D) in a deal originally announced last year, but contingent upon Chromos raising at least $Cdn6mm ($5.26mm) in a private placement. (Concurrent with the acquisition the company raised the money.)
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chromos acquires Targeted Molecules Corp.
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice